Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 23:2021:8881115.
doi: 10.1155/2021/8881115. eCollection 2021.

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome

Andrew Toma  1 , Christina Darwish  2 , Michele Taylor  1 , Justin Harlacher  1 , Ribal Darwish  1
Affiliations

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome

Andrew Toma et al. Crit Care Res Pract. .

Abstract

Objective: Currently, management of acute respiratory distress syndrome (ARDS) in COVID-19 infection with invasive mechanical ventilation results in poor prognosis and high mortality rates. Interventions to reduce ventilatory requirements or preclude their needs should be evaluated in order to improve survival rates in critically ill patients. Formation of neutrophil extracellular traps (NETs) during the innate immune response could be a contributing factor to the pulmonary pathology. This study suggests the use of dornase alfa, a recombinant DNAse I that lyses NETs, to reduce ventilatory requirements and improve oxygenation status, as well as outcomes in critically ill patients with ARDS subsequent to confirmed or highly suspected COVID-19 infection.

Design: A single-institution cohort study. Setting. Intensive care unit in a tertiary medical center. Patients. Adult patients with acute respiratory distress syndrome (ARDS) admitted to the ICU with confirmed COVID-19 infection. Intervention. Treatment with aerosolized dornase alfa. Measurements and Main Results. Of 39 patients evaluated, most patients had improvement in oxygenation measured by increase in the PaO2/FiO2 ratio, reduction in ventilatory support or other supportive oxygen requirements, and partial resolution of bilateral opacities visible on CXR, as well as improved outcome.

Conclusions: Administration of inhalational dornase alfa via a filtered nebulizer medication system or through an adapter in a ventilator circuit should be considered in all COVID-19-positive patients with ARDS as early in the disease course as possible.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Demonstration of mechanism utilized for aerosolized dornase alfa administration: (a) AirLife® Misty Max 10TM nebulizer medication system with filter and (b) AirLife® Tee adapter with valve in conjunction with a small volume nebulizer.
Figure 2
Figure 2
Chest X-rays of patients II, IV, and VII before (A) and after (B) treatment with dornase alfa. Imaging demonstrates improved resolution of opacities including for those who had prolonged mechanical ventilation (patients II, P2A/B, and VII, P7A/B) and for those not requiring mechanical ventilation (patient IV, P4A/B).
See this image and copyright information in PMC

References

    1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
    1. Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine. 2020;180(7):934–1010. doi: 10.1001/jamainternmed.2020.0994. - DOI - PMC - PubMed
    1. Li X., Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Critical Care. 2020;24(1):p. 198. doi: 10.1186/s13054-020-02911-9. - DOI - PMC - PubMed
    1. Richardson S., Hirsch J. S., Narasimhan M., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2058. doi: 10.1001/jama.2020.6775. - DOI - PMC - PubMed
    1. Earhart A. P., Holliday Z. M., Hofmann H. V., Schrum A. G. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome. New Microbes and New Infections. 2020;35 doi: 10.1016/j.nmni.2020.100689.100689 - DOI - PMC - PubMed

LinkOut - more resources